Dropless Pars Plana Vitrectomy Using Intravitreal Decanted Triamcinolone and Moxifloxacin: Safety and Efficacy

Area of Science:

• Ophthalmology
• Retina Surgery
• Pharmacology

Background:

• Pars plana vitrectomy (PPV) is a common surgical procedure.
• Postoperative inflammation and complications like cystoid macular edema (CME) can affect visual outcomes.
• Standard postoperative care involves topical anti-inflammatory eye drops.

Purpose of the Study:

• To compare a dropless intravitreal regimen of triamcinolone acetonide and moxifloxacin with standard topical therapy after PPV.
• To evaluate the safety and efficacy of this dropless approach.

Main Methods:

• Retrospective study of patients undergoing PPV.
• Dropless cohort received intravitreal triamcinolone and moxifloxacin.
• Control cohort received topical moxifloxacin and prednisolone acetate.
• Outcomes assessed: intraocular inflammation, IOP, CST, CME, and BCVA.

Main Results:

• The dropless group showed significantly less anterior chamber inflammation and lower central subfield thickness (CST) at multiple time points.
• Reduced incidence of cystoid macular edema (CME) and greater improvement in best-corrected visual acuity (BCVA) were observed in the dropless group.
• Intraocular pressure (IOP) was similar, and no endophthalmitis occurred. Findings were consistent for epiretinal membrane (ERM) subgroup.

Conclusions:

• A dropless intravitreal regimen is a safe and effective alternative to topical therapy post-PPV.
• This approach leads to reduced postoperative inflammation and CME.
• Improved visual outcomes are associated with the dropless intravitreal regimen.